Inhibition of the renin-angiotensin system in chronic kidney disease: A critical look to single and dual blockade

Nephron - Clinical Practice

Volumn 113, Issue 4, 2009, Pages

  Locatelli, Francesco ^a   Del Vecchio, Lucia ^a   Cavalli, Andrea ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme (ACE) inhibitors; Chronic kidney disease; Dual blockade; Hypertension; Proteinuria

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN; RAMIPRIL; TELMISARTAN; VALSARTAN;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HYPERTENSION; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; KIDNEY FAILURE, CHRONIC; PREVALENCE; TREATMENT OUTCOME;

EID: 69549116047     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235946     Document Type: Short Survey

References (37)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
2. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939-945.
3. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-1863.
4. Jafar TH, Schmid CH, Landa M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87.
5. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
6. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869. (Pubitemid 34940825)
7. Hou FF, Zhang X, Zhang GH, et al: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131-140.
8. Wright JT Jr, Bakris G, Greene T, et al: African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 2002; 288: 2421-2431.
9. Hemmelgarn BR, Zhang J, Manns BJ, et al: Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int 2006; 69: 2155-2161.
10. van Dijk MA, Breuning MH, Duiser R, et al: No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2003; 18: 2314-2320.
11. Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD: Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2008; 23: 573-579.
12. Chapman AB: Approaches to testing new treatments in autosomal dominant polycystic kidney disease: Insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol 2008; 3: 1197-1204.
13. Casas JP, Chua W, Loukogeorgakis S, et al: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and metaanalysis. Lancet 2005; 366: 2026-2033.
14. Rahman M, Pressel S, Davis BR, et al: Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs. a diuretic: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 936-946.
15. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961.
16. Shoda J, Kanno Y, Suzuki H: A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. Intern Med 2006; 45: 193-198.
17. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
18. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET Investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
19. Reyes AJ: Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003; 17: 397-414.
20. Tagami T, Yamamoto H, Moriyama K, et al: A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology 2009; 150: 862-870.
21. Bakris G, Burgess E, Weir M, Davidai G, Koval S, AMADEO Study Investigators: Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008; 74: 364-369.
22. Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C, VIVALDI Investigators: Antiproteinuric effects of angiotensin receptor blockers: Telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008; 23: 3174-3183.
23. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 2003; 361: 117-124. (Pubitemid 36092015)
24. Kunz R, Friedrich C, Wolbers M, Mann JF: Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48.
25. Kunz R, Wolbers M, Glass T, Mann JF: The COOPERATE trial: A letter of concern. Lancet 2008; 371: 1575-1576.
26. Catapano F, Chiodini P, Nicola LD, et al: Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: Meta-analysis and metaregression. Am J Kidney Dis 2008; 52: 475-485.
27. Bakris GL, Ruilope L, Locatelli F, et al: Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial. Kidney Int 2007; 72: 879-885.
28. Tuttle KR: Albuminuria reduction: The holy grail for kidney protection. Kidney Int 2007; 72: 785-786.
29. Berl T: Maximizing inhibition of the reninangiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers. Nephrol Dial Transplant 2008; 23: 2443-2447.
30. Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH: Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: A doubleblind randomized cross-over study. Diabetes Care 2003; 26: 150-155.
31. Shojoedt KJ, Atrup A, Persson F, et al: Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy. Proceeding from the European Association for the Study of Diabetes (EASD), 2007.
32. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH: Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68: 1190-1198.
33. Hollenberg NK, Parving HH, Viberti G, et al: Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921-1926.
34. Hou FF, Xie D, Zhang X, et al: Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007; 18: 1889-1898.
35. Mori-Takeyama U, Minatoguchi S, Murata I, et al: Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis. Clin Exp Nephrol 2008; 12: 33-40.
36. Locatelli F, Pozzoni P: Chronic kidney disease in the elderly: Is it really a premise for overwhelming renal failure? Kidney Int 2006; 69: 2118-2120.
37. Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, et al: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensinconverting enzyme inhibitors: A randomised controlled trial. Lancet 2008; 372: 1174-1183.